undamentalytics Newsletter
Sign in

Kura Oncology, Inc. (KURA) stock

Add to watchlist

Add holding +

NASDAQ: KURA Nasdaq Biotechnology Next results ~November 3, 2026

Kura Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$15

Valuation models combined (2)

Base case. Range ~$7.2–$17. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Kura Oncology, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling2 purchases and 39 sales by directors and officers, last 12 monthsInsider trades
  • Funds115 adding, 88 cuttingOf 35 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Current signal Capital expenditure surging: TTM capex grew 167% year over year and now absorbs 7.3% of revenue.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -411.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -152.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 50.4% of revenue: a real cost that cash-flow figures leave out.
  • High sales multiple. The shares trade at 11 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 57% and a beta of 1.4 against the S&P 500.
  • Heavily shorted. 16.5% of the shares available to trade are sold short (8.0 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
-$0.77 against an average estimate of -$0.88: beat by 12.1%
Revenue
$21m, up 36.5% on a year earlier
Share reaction
+1.6% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.81

Kura Oncology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.6%
  • 1 week+1.8%
  • 1 month-8.1%
  • This year-5.8%
  • 1 year-4.7%
  • 5 years-46.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$77.2M
Operating margin
-411.9%
Net margin
-384.3%
EPS (TTM, diluted)
$-3.36

Growth

Share count change
+1.2%

Cash

Free cash flow (TTM)
-$117M
FCF margin
-152.1%
Stock pay % of revenue
50.4%

Earnings

Last results
August 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Insider trade
  4. Insider trade
  5. Results
  6. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Kura Oncology, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Kura Oncology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.16 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$17 ~$10–$24 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.2 ~$7.4–$28 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$15 ~$7.2–$17 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kura Oncology, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025Now
Share price$14.38$8.71$10.39$9.79
Market value$1.1bn$750m$911m$864m
+ Net debt (− = net cash)−$28m−$215m−$139m−$60m
Enterprise value$1.0bn$536m$772m$804m
Multiples
Price / sales —13.9x13.5x11.2x
Price / earnings ————
Price / free cash flow —5.6x——
EV / EBITDA ————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $24m and EPS of −$0.81 (range −$0.99 to −$0.70) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.17 +0% $97m +43%
Next −$2.35 +26% $210m +117%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −8.2% on 90 days ago. In the last 30 days, 7 analysts raised Kura Oncology, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Kura Oncology, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.46 Current fiscal year, 60 days ago: −$3.23 Current fiscal year, 30 days ago: −$3.16 Current fiscal year, 7 days ago: −$3.17 Current fiscal year, Now: −$3.17 −$3.17 Next fiscal year, 90 days ago: −$2.60 Next fiscal year, 60 days ago: −$2.30 Next fiscal year, 30 days ago: −$2.30 Next fiscal year, 7 days ago: −$2.35 Next fiscal year, Now: −$2.35 −$2.35

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.46−$2.60
60 days ago −$3.23−$2.30
30 days ago −$3.16−$2.30
7 days ago −$3.17−$2.35
Now −$3.17−$2.35

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.88 −$0.77 +12.1%
Dec 2025 −$0.49 −$0.92 −88.6%
Sept 2025 −$0.68 −$0.85 −25.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 12, 2026

No numeric guidance in Kura Oncology, Inc.'s latest earnings release (filed August 12, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

16 analysts, Oct 2026
Buy1594%
Hold16%
Sell00%

Monthly trend

  1. Oct 202631216
  2. Sep 202621215
  3. Aug 202621215
  4. Jul 202621215

Counts of recommendations published by analysts covering Kura Oncology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.5%
of tradable shares
Days to cover
7.97
at average volume
Short interest, 1 month
−3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.4%
of shares
Employees
260
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
KURA−57%−11%+16%−39%+19%−6%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
KURA25%50%42%50%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
KURA−69%−42%−48%−64%−39%−33%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 87% from November 2, 2015 to July 5, 2016. Getting back needed a 678% gain, reached on January 24, 2018, 568 days after the low.

Price behaviour

52-week range
$7.40 – $13.59
From 52-week high
−28.0%
vs 50-day average
−11.9%
vs 200-day average
−0.2%
Volatility (1 year)
57%
Beta vs S&P 500
1.38

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±2.6%
After a week
7 up, 5 down
typical move ±7.8%
After a month
6 up, 6 down
typical move ±13.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 +1.6% +0.9% +26.2% +14.7%
May 12, 2026 −0.3% +0.4% −5.8% −6.8%
March 5, 2026 +4.8% −1.9% +3.4% −0.7%
January 12, 2026 −2.1% 0.0% −8.6% −16.7%
November 4, 2025 +1.7% −0.8% +9.4% +22.6%
August 7, 2025 −8.1% +0.7% +9.5% +35.0%
May 1, 2025 −1.4% +2.2% −8.5% −4.0%
February 26, 2025 −2.9% −1.5% −6.5% −9.4%
November 7, 2024 −0.9% +1.2% −7.6% −41.0%
August 8, 2024 +2.2% +2.8% +4.7% +5.3%
May 2, 2024 +1.7% +2.2% +2.4% +4.5%
February 27, 2024 +3.1% +0.1% +1.4% +2.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 54 67 77
EBITDA −165 −192 −303 −317
Operating income −166 −193 −304 −318
Net income −153 −174 −279 −297
Diluted EPS −$2.08 −$2.02 −$3.18 −$3.36
Growth (year on year)
Revenue — — +25.2% —
Margins
EBITDA margin — −357.0% −448.4% −410.2%
Operating margin — −358.5% −449.9% −411.9%
Net margin — −322.9% −412.9% −384.3%
Free-cash-flow margin — 248.4% −104.8% −152.1%
Cash flow
Cash from operations −125 134 −64 −112
Capital spending 0 0 7 6
Free cash flow −125 134 −71 −117
Stock-based pay 28 34 37 39
Free cash flow after stock pay −153 100 −108 −156
Balance sheet
Cash 37 224 149 70
Total debt 9 10 10 10
Net debt (negative = net cash) −28 −215 −139 −60
Diluted shares 73m 86m 88m 88m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · June 30, 2026
What it owns · $588m
Short-term assets $559mLonger-term assets $28m
What it owes, and who funded it · $588m
Short-term liabilities $118mLonger-term liabilities $421mShareholders' equity $48m
  • Short-term assets cover short-term liabilities $559m of assets due within a year against $118m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $559m short-term assets against $421m of longer-dated liabilities.
  • More cash than debt $70m of cash against $10m of debt.
  • Debt below 40% of shareholders' equity Debt is 20% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 1% to 20% over five years.
  • A year's operating cash flow covers at least 20% of debt −$112m of operating cash flow against $10m of debt.
  • Operating profit covers interest at least five times over Operating income of −$318m against $1m of interest.

From Kura Oncology, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.2%
year over year
R&D spending
336.0%
of revenue
Days sales outstanding
45 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated KURA ADCT ASMB AAPG PLX CGEN Median
Revenue, last 12 months $77m $80m $75m $80m $81m $73m $58m
Revenue growth, last 12 months — 3.0% 125.1% −41.4% 30.1% 161.1% 12.6%
Revenue growth, 3-year average — — −3.3% — 6.1% 302.6% 13.7%
Revenue growth, latest quarter 36.5% 2.2% 38.9% — 27.1% — 10.2%
Gross margin — — — 91.5% 69.2% 87.3% 82.9%
Operating margin −411.9% −125.1% −11.8% — 28.9% 43.1% −191.1%
Operating margin, 3-year average — −171.7% −126.0% — 1.1% −255.7% −363.5%
Net margin −384.3% −121.8% −0.1% −216.5% 23.5% 48.6% −172.8%
Cash from operations / revenue −144.7% −128.5% −51.4% −204.5% 12.3% 43.5% −162.3%
Free-cash-flow margin −152.1% −128.5% −51.5% −209.3% 9.5% 43.1% −156.7%
Free-cash-flow margin, 3-year average — −171.3% −35.8% — −2.3% −216.6% −310.0%
Stock pay / revenue 50.4% 12.2% 8.9% 3.6% 2.4% 2.6% 20.7%
Change in share count 1.2% 38.3% 50.8% 17.9% −4.1% 4.8% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
License and Collaboration Revenue $65.3M ▲ 21.3%
Collaboration Revenue $65.3M ▲ 21.3%
Products $2.1M —

These categories overlap or exclude eliminations, so shares aren't shown.

From Kura Oncology, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$956M
Institutions reporting
218
Shares held vs prior quarter
▲ 3.3%
Positions opened / closed
24 / 24

Top buyers and sellers, Q2 2026: 115 institutions bought and 88 sold ; the biggest buyer was Arrowstreet Capital, Limited Partnership (+1.4M shares) and the biggest seller Prosight Management, LP (−1.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $115M 10.5M 12.1% ▲ 9.0%
Montanova Capital, LLC $94.1M 8.6M 9.8% 0.0%
Bvf Inc $92.7M 8.4M 9.7% 0.0%
State Street Corp $58.5M 5.3M 6.1% ▲ 18.1%
Vanguard Capital Management LLC $43M 3.9M 4.5% ▲ 3.4%
Armistice Capital, LLC $40.3M 3.7M 4.2% ▼ 1.6%
AQR Capital Management LLC $34.3M 3.1M 3.6% ▲ 47.2%
Goldman Sachs Group Inc $24.8M 2.3M 2.6% ▲ 58.0%
Geode Capital Management, LLC $24.5M 2.2M 2.6% ▲ 9.6%
Alethea Capital Management, LLC $23.8M 2.2M 2.5% ▲ 41.8%
Prosight Management, LP $22.2M 2.0M 2.3% ▼ 39.8%
Deep Track Capital, LP $21.7M 2.0M 2.3% ▼ 25.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kura Oncology, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2.4M 2 trades by 1 insider, last 12 months Insider sales History → $3.8M 39 trades by 7 insiders · 71% under pre-set plans
Net ▼ $1.5M net selling
Insider Date Trade Shares Price Value
Powl Brian T. Chief Commercial Officer September 29, 2026 Sell pre-set plan 15,430 $10.75 $165,872
Leoni Mollie Chief Medical Officer September 29, 2026 Sell pre-set plan 28,802 $10.75 $309,622
Ford Kathleen Chief Operating Officer September 29, 2026 Sell pre-set plan 3,668 $10.75 $39,431
Powl Brian T. Chief Commercial Officer September 28, 2026 Sell pre-set plan 8,000 $10.56 $84,480
Powl Brian T. Chief Commercial Officer September 28, 2026 Sell pre-set plan 9,020 $10.50 $94,710
Doyle Thomas James SVP, Finance & Accounting September 28, 2026 Sell 4,607 $10.50 $48,374
Leoni Mollie Chief Medical Officer September 28, 2026 Sell pre-set plan 12,448 $10.50 $130,704
Ford Kathleen Chief Operating Officer September 28, 2026 Sell pre-set plan 6,906 $10.50 $72,513
Bair Teresa Brophy Chief Legal Officer September 28, 2026 Sell pre-set plan 8,442 $10.50 $88,641
Burrows Francis Chief Scientific Officer September 24, 2026 Sell 20,726 $10.83 $224,463
Wilson Troy Edward President and CEO August 24, 2026 Buy 100,000 $12.39 $1.2M
Powl Brian T. Chief Commercial Officer August 21, 2026 Sell pre-set plan 4,345 $11.89 $51,662

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Kura Oncology, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Chris Jacobs(R-NY 27):Purchase, $1,001 - $15,000, traded December 12, 2022, filed January 20, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 30, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 12, 2026
  • March 5, 2026
  • January 12, 2026
  • November 4, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Kura Oncology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Kura Oncology, Inc. in brief

What does Kura Oncology, Inc. do?
Kura Oncology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Kura Oncology, Inc.'s stock ticker?
Kura Oncology, Inc. trades under the ticker KURA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Kura Oncology, Inc.'s free cash flow?
Kura Oncology, Inc.'s free-cash-flow margin is -152.1% of revenue over the trailing twelve months.
Who are Kura Oncology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Montanova Capital, LLC and Bvf Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Kura Oncology, Inc.'s market cap?
On November 2, 2026, Kura Oncology, Inc.'s market capitalisation was about $864M and net debt of -$60.5M. Market figures come from third-party market data and may be delayed.
How much debt does Kura Oncology, Inc. have?
Kura Oncology, Inc.'s debt-to-equity ratio is 20.2%, from its latest balance sheet (0.7% five years earlier). The financial health section below sets out its other solvency checks.
Who are Kura Oncology, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Kura Oncology, Inc. are ADC Therapeutics SA, Assembly Biosciences, Inc., Ascentage Pharma Group International, Protalix Biotherapeutics, Inc. and Compugen LTD. The side-by-side comparison below sets their revenue, margins and growth against Kura Oncology, Inc.'s.
Are insiders buying or selling Kura Oncology, Inc. stock?
Over the last 12 months, Kura Oncology, Inc.'s directors and officers reported 2 open-market purchases and 39 sales on Form 4. The insider trading page charts every trade.
When is Kura Oncology, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kura Oncology, Inc. announces its own schedule.